sacituzumab govitecan-hziy (Trodelvy)
sacituzumab govitecan-hziy is an FDA-licensed reference biologic from Gilead Sciences, Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2020
Reference approved
Reference product
Trodelvy sacituzumab govitecan-hziy
Gilead Sciences, Inc.
- Approved
- Apr 22, 2020
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for sacituzumab govitecan-hziy, in chronological order.
Reference approval
Approval date of the reference sacituzumab govitecan-hziy product.
6 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for sacituzumab govitecan-hziy (Trodelvy)?
No 351(k) biosimilars or interchangeable biosimilars referencing sacituzumab govitecan-hziy are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.